Benedito A Carneiro, MD, MS is a Medical Oncologist and clinical investigator with research interests in early drug development and first-in-human trials exploring novel therapeutics for solid tumors and genitourinary cancers. Dr. Carneiro is the founder and Director of the Cancer Drug Development Program (Phase I), Director of Clinical Research at the Lifespan Cancer Institute, Associate Director of the Division of Hematology/Oncology, and Co-Leader of the Cancer Therapeutics Program at the Legorreta Cancer Center at Brown University. Dr. Carneiro is the Principal Investigator of numerous first-in-human (phase I) clinical trials evaluating novel treatments for advanced solid tumors, including kidney, bladder, prostate, lung, pancreas, and colon cancers. Under his leadership, the clinical trial program at the Lifespan Cancer Institute and the Legorreta Cancer Center at Brown University expanded significantly with a remarkable impact in the region by creating opportunities for patients in Rhode Island to access the most advanced cancer treatments in development in the world. The availability of phase I trials has prevented many patients and their family members from traveling to neighboring states to access promising treatment options. The growing infrastructure for clinical research aligned with a multidisciplinary team of experts has positioned the Brown Phase I program at the forefront of drug development globally. Effective collaborations with biotech and industry leaders in the pharmaceutical sector have advanced strategic academic alliances catalyzing scientific discoveries across the campus. Dr Carneiro's clinical and translational research efforts explore innovative immunotherapies and genomic-driven treatment strategies, cellular therapy, target discovery, and biomarkers of treatment response and resistance mechanisms in collaboration with translational scientists. Dr. Carneiro has expertise and interest in the mechanisms of cell death (apoptosis) and its interface with anti-tumor immune response and novel agents targeting tumors with defects in DNA repair mechanisms. Ongoing research projects involving post-doctoral researchers, graduate students, and medical students investigate novel strategies to treat advanced prostate cancer with immunotherapies and drugs disrupting the cellular DNA repair machinery and mechanisms of therapy-induced senescence.
Dr. Carneiro was Co-Director of the Developmental Therapeutics Program at the Lurie Comprehensive Cancer Center, Northwestern University. He was the Director of the postgraduate Developmental Therapeutics Fellowship Program at Northwestern University Feinberg School of Medicine. He has published over 110 articles in peer-reviewed journals and multiple book chapters. He has been a Principal Investigator or Co-Investigator in over 120 clinical trials. He is a member of several professional societies, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the American Association of Cancer Research (AACR). He represents the Legoretta Cancer Center at the WIN (Worldwide Innovative Networking in Personalized Cancer Medicine) Consortium. He is an active AACR Annual Meeting Clinical Trials Committee member and has participated in the ASCO Annual Meeting Scientific Program Committee.
